ENDOMETRIAL CANCER TREATMENTS
Keywords:
endometrial cancer, obesity, signs, tests, treatment options, prognosisAbstract
Endometrial cancer, a type of cancer that affects the lining of the uterus, is the most common gynecological cancer in developed countries. According to the American Cancer Society, approximately 65,000 new cases of endometrial cancer are diagnosed annually in the United States alone. The prognosis for patients with endometrial cancer largely depends on the timely and effective administration of treatment. Fortunately, significant advancements in medical technology and research have led to the development of various treatment options, each with its own set of benefits and drawbacks. This article aims to provide a comprehensive overview of the current treatments available for endometrial cancer, highlighting their mechanisms, efficacy, and potential risks.
References
Colombo N, McMeekin DS, Schwartz PE, et al.: Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 108 (5): 1021-6, 2013.
Tsoref D, Welch S, Lau S, et al.: Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135 (2): 184-9, 2014.
Slomovitz BM, Jiang Y, Yates MS, et al.: Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33 (8): 930-6, 2015.
Aghajanian C, Sill MW, Darcy KM, et al.: Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29 (16): 2259-65, 2011.
Alvarez EA, Brady WE, Walker JL, et al.: Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 129 (1): 22-7, 2013.
Makker V, Colombo N, Casado Herráez A, et al.: Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety from the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol 41 (16): 2904-2910, 2023.
